Alim Namitokov

Dr. Alim Namitokov

Kuban State Medical Academy, Krasnodar, Russian Federation
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MYM. V. Yezhov
M. V. Yezhov
SBS. A. Bliznyuk
S. A. Bliznyuk
NTNarek Tmoyan
Narek Tmoyan
TRT. A. Rozhkova
T. A. Rozhkova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ТКТ. Ю. Кузнецова
Т. Ю. Кузнецова
Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС)

10 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKSofia Kruchinova
Sofia Kruchinova
MGMilana Gendugova
Milana Gendugova
Alim NamitokovAlim Namitokov
Alim Namitokov
MSMaria Sokolskaya
Maria Sokolskaya
IGIrina Gilevich
Irina Gilevich
Vladimir ShvartzVladimir Shvartz
Vladimir Shvartz
Background: Despite the vast evidence of the beneficial effect of vagus nerve stimulation on the course of myocardial infarction confirmed in studies using animal models, the introduction of this method into actual clinical practice remains uncommon. Objective: The objective of our study was to evaluate the effect of transcutaneous vagus nerve stimulation (tVNS) on in-hospital and long-term outcomes for patients with ST-elevation myocardial infarction. Materials and Methods: A blind, randomized, placebo-controlled clinical trial was conducted. The participants were randomly split into two groups. The Active tVNS group was subjected to stimulation of the tragus containing the auricular branch of the vagus nerve. The Sham tVNS group underwent stimulation of the lobule. Stimulation was performed immediately on admission before the start of the percutaneous coronary intervention (PCI). Then, tVNS continued throughout the entire PCI procedure and 30 min after its completion. The primary endpoints were hospital mortality and 12-month mortality. The secondary endpoints were in-hospital and remote non-lethal cardiovascular events. The combined endpoint consisted of major adverse cardiovascular events (MACEs)—recurrent myocardial infarction, stroke/TIA, and overall mortality. Results: A total of 110 patients were randomized into the Active tVNS group (n = 55) and the Sham tVNS group (n = 55). The incidences of hospital mortality, cardiogenic shock, and AV block 3 were statistically less common in the Active tVNS group than in the Sham tVNS group (p = 0.024*, p = 0.044*, and p = 0.013*, respectively). In the long-term period, no statistical differences were found in the studied outcomes obtained following the construction of Kaplan–Meyer survival curves. When comparing groups by total mortality, taking into account hospital mortality, we observed a tendency for the survival curves to diverge (Logrank test, p = 0.066). Statistical significance was revealed by the composite endpoint, taking into account hospital events (Logrank test, p = 0.0016*). Conclusions: tVNS significantly reduced hospital mortality (p = 0.024*), the level of markers of myocardial damage, and the frequency of severe cardiac arrhythmias in patients with acute myocardial infarction. In the long term, the prognostic value of tVNS was revealed by the composite endpoint major adverse cardiovascular events. Further studies with an expanded sample are needed for a more detailed verification of the data obtained to confirm the effectiveness of tVNS and allow an in-depth analysis of the safety and feasibility of its use in routine clinical practice. This clinical trial is registered with ClinicalTrials database under a unique identifier: NCT05992259.

16 October 2024 in Life
Verified
Journal Article
Open access
PDF file
Alim NamitokovAlim Namitokov
Alim Namitokov
КККарина Карабахциева
Карина Карабахциева
OMOlga Malyarevskaya
Olga Malyarevskaya
Introduction: Atherosclerosis is a leading cause of cardiovascular disease, characterized by lipid accumulation and chronic inflammation within arterial walls. Early detection in young adults is crucial for preventing adverse cardiovascular events. This study investigates the associations between inflammatory indices, lipid biomarkers, and the presence of atherosclerosis in patients aged 18 to 55 years. Methods: A cross-sectional study was conducted involving 89 participants divided into two groups: 62 patients with documented atherosclerosis (main group) and 27 healthy controls without significant atherosclerosis. Comprehensive data—including demographic information, medication use, imaging results, laboratory parameters, and calculated inflammatory indices (SIRI, SII, AISI, NLR, PLR, MLR)—were collected. Statistical analyses included correlation assessments, group comparisons using the Mann–Whitney U test, logistic regression modeling, feature importance analysis with Random Forest and Gradient Boosting classifiers, receiver operating characteristic (ROC) curves, and K-means clustering. Results: Significant differences were observed between the main and control groups. Patients with atherosclerosis exhibited elevated inflammatory indices (SIRI, NLR, MLR, SII) and lipid profile abnormalities (higher TC and LDL-C, lower HDL-C). Lp(a) and ANGPTL3 levels were significantly higher in the main group (p < 0.001 and p < 0.01, respectively). Logistic regression identified SIRI and ANGPTL3 as significant predictors of atherosclerosis, with the model demonstrating high accuracy (77%) and sensitivity (93%). Feature importance analysis confirmed the significance of SIRI and ANGPTL3, alongside traditional lipid biomarkers, in predicting disease presence. ROC analysis showed excellent model performance (AUC > 0.80). Clustering analysis revealed two distinct patient subgroups characterized by predominant inflammatory profiles or lipid metabolism disturbances. Conclusions: Systemic inflammation and lipid abnormalities play significant roles in early atherosclerosis among young adults. Elevated SIRI and ANGPTL3 levels are potent predictors of disease presence. The integration of inflammatory indices and lipid biomarkers into predictive models enhances risk stratification and supports personalized medicine approaches.

11 May 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Alim NamitokovAlim Namitokov
Alim Namitokov
OIO. P. Ishevskaya
O. P. Ishevskaya
VFV. I. Fetisova
V. I. Fetisova
EKE. D. Kosmacheva
E. D. Kosmacheva
VPV. A. Porkhanov
V. A. Porkhanov
The novel coronavirus infection COVID-19 pandemic has spread to more than 180 countries. Cardiovascular patients belong to one of the susceptible population cohorts. There is a peculiar pathogenesis and variety of clinical manifestations of COVID-19, as well as difficulties with early diagnosis. Other unresolved issues are routing, surgery and therapy of such patients and comorbidities. Due to absence of well-defined algorithms and guidelines, the treatment of patients with acute coronary syndrome (ACS) in different countries is carried out differently. Interactions between antiviral and coronary artery disease medications are also not completely clear. Based on the available data, the main organizational and therapeutic approaches for ACS during the COVID-19 pandemic are reflected.

24 April 2023 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
TRT.A. Rozhkova
T.A. Rozhkova
BTB.M. Tamaeva
B.M. Tamaeva
ASA.A. Sokolov
A.A. Sokolov
SBS.E. Bednova
S.E. Bednova
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить комплаентность пациентов с гетерозиготной семейной гиперхолестеринемией (геСГХС) в течение 5-летнего периода работы регистра РЕНЕССАНС (Регистр пациентов с СГХС и пациентов очень высокого сЕрдечно-Сосудистого риска с недоСтАточной эффективНоСтью, проводимой гиполипидемической терапии). МАТЕРИАЛ И МЕТОДЫ РЕНЕССАНС является открытым, национальным, наблюдательным исследованием и включает больных с СГХС. Проводилась оценка факторов риска атеросклероза, анамнеза сердечно-сосудистых заболеваний (ССЗ), интенсивности гиполипидемической терапии (ГЛТ). Каждому пациенту определены уровни общего холестерина, триглицеридов, холестерина липопротеидов высокой плотности в сыворотке крови. Содержание холестерина липопротеидов низкой плотности (ХС ЛНП) рассчитывали по формуле Фридвальда. РЕЗУЛЬТАТЫ В исследование включено 2317 пациентов с геСГХС, из которых 58% — женщин. При включении в регистр 59% больных относились к категории высокого сердечно-сосудистого риска. Динамический визит проведен у 47% пациентов, период наблюдения составил 24 [11; 42] мес. Больные с динамическим визитом чаще имели определенный диагноз геСГХС и отягощенный наследственный анамнез по ССЗ, были моложе и им в более раннем возрасте диагностировали СГХС (p<0,05). У пациентов без динамического визита были распространены модифицируемые факторы риска (p<0,001). Среди пациентов высокого сердечно-сосудистого риска 54% больных получали ГЛТ, очень высокого — 86%. За время наблюдения в регистре доля принимающих ГЛТ пациентов увеличилась с 59 до 78%, в том числе статинами в режиме высокой интенсивности с 36 до 54%, в комбинации с эзетимибом — с 15 до 34%, ингибиторами PCSK9 — с 4 до 14% (p<0,001 для всех). Целевого уровня ХС ЛНП достигли 13% пациентов. Данные симуляционного анализа продемонстрировали, что для адекватного контроля уровня ХС ЛНП, не менее 92,5% больных с геСГХС в регистре должны получать трехкомпонентную ГЛТ со статинами, эзетимибом и ингибиторами PCSK9. ЗАКЛЮЧЕНИЕ 5-летнее наблюдение за участниками регистра РЕНЕССАНС демонстрирует увеличение использования многокомпонентных схем лечения, но недостаточное для адекватного контроля ХС ЛНП.

24 June 2024 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
Alim NamitokovAlim Namitokov
Alim Namitokov
Background: This comprehensive review explores the multifaceted role of sortilin, a key receptor in lipid metabolism, within the context of cardiovascular diseases (CVDs), the leading cause of global mortality. Main body: Sortilin, encoded by the SORT1 gene, is implicated in the pathogenesis of atherosclerosis, primarily through its regulation of low-density lipoprotein cholesterol (LDL-C) and very low-density lipoproteins (VLDL). The review delves into the biological functions of sortilin, emphasizing its critical role in lipid and cholesterol homeostasis and its influence on hepatic secretion of lipoproteins and atherogenesis. We highlight sortilin's pathophysiological significance in atherosclerosis, underscoring its involvement in lipid metabolism pathways and vascular inflammation, and its impact on macrophage functions in atherosclerotic plaque formation. The potential of sortilin as a therapeutic target is discussed, considering evidence that suggests its modulation could ameliorate atherosclerosis. The review also acknowledges current inconsistencies and gaps in the evidence, calling for more comprehensive patient studies and in-depth mechanistic research. Finally, the article outlines future research directions, focusing on understanding sortilin's specific cellular mechanisms in cardiovascular health, exploring its genetic variability, therapeutic implications, and its broader relevance to other diseases. Conclusion: This review underscores the significance of sortilin as a biomarker and a promising target for therapeutic intervention in cardiovascular pathology, while advocating for continued research to fully unravel its complex role.